Venoarterial extracorporeal membrane oxygenation, or VA ECMO, is a form of temporary life support that takes over both the pumping and gas-exchange functions of a failing heart and lungs. Blood is drawn out of a large vein, run through an external membrane oxygenator that adds oxygen and removes carbon dioxide, and then pushed back into an artery so it flows through the body. The technology emerged in the 1970s as an offshoot of cardiopulmonary bypass used in heart surgery, and it has since become a last-resort intervention for patients in severe cardiogenic shock or cardiac arrest who are not responding to conventional treatments. While VA ECMO can stabilize someone on the edge of death, it introduces a cascade of physiological trade-offs and complications that make its management one of the most demanding tasks in critical care.
How VA ECMO Differs from VV ECMO
The two main configurations of ECMO serve fundamentally different purposes. Venovenous (VV) ECMO drains blood from a vein, oxygenates it, and returns it to another vein. Because the blood re-enters the venous system, the patient’s own heart still has to pump it forward through the lungs and out to the body. VV ECMO helps the lungs but does nothing for a failing heart. VA ECMO, by contrast, returns the oxygenated blood directly into an artery, bypassing the heart entirely. This provides both circulatory support and respiratory support at the same time.1PubMed Central. ECMO physiology That dual capability is what makes VA ECMO the configuration of choice when the heart itself is the primary problem.
When VA ECMO Gets Deployed
The most common indication is cardiogenic shock, a state in which the heart cannot pump enough blood to keep organs alive despite maximum drug therapy. This can happen after a massive heart attack, after cardiac surgery that leaves the heart too stunned to recover on its own, or during fulminant myocarditis when sudden inflammation cripples the heart muscle. VA ECMO has also become a salvage intervention during cardiac arrest that does not respond to standard CPR.2PubMed. Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest In all these scenarios, the idea is to buy time: keep the organs perfused while clinicians figure out whether the heart will recover, whether the patient can be bridged to a ventricular assist device, or whether transplant is feasible.
Survival rates depend heavily on the underlying cause. Fulminant myocarditis is one of the more favorable indications because the heart inflammation can resolve, and registry data show that roughly two-thirds of myocarditis patients supported with VA ECMO survive to hospital discharge.3PubMed. Outcomes With Peripheral Venoarterial Extracorporeal Membrane Oxygenation for Suspected Acute Myocarditis Long-term survival after myocarditis-related VA ECMO ranges from about 65% to over 90% across studies.4PubMed Central. Fulminant Myocarditis and Venoarterial Extracorporeal Membrane Oxygenation: A Systematic Review Postcardiotomy shock and refractory cardiac arrest carry worse numbers, and outcomes in those groups vary widely depending on how quickly support is initiated and what institutional expertise is available.
Peripheral Versus Central Cannulation
VA ECMO can be set up two ways. In peripheral cannulation, the drainage and return cannulas are placed into blood vessels in the groin, typically the femoral vein and femoral artery. This can be done at the bedside, in an emergency room, or even in the field, because it does not require opening the chest. In central cannulation, the cannulas go directly into the right atrium and ascending aorta through an open chest, which is why it is most often used during or right after cardiac surgery.
The choice carries real consequences. A meta-analysis of postcardiotomy shock patients found that peripheral VA ECMO was associated with lower in-hospital and 30-day mortality compared with central cannulation. Central placement carried higher odds of reoperation for bleeding and greater transfusion needs.5Journal of Thoracic and Cardiovascular Surgery. Cannulation Strategy in Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock Central cannulation also appears as an independent risk factor for intracranial bleeding.6PubMed Central. Ischemic and hemorrhagic brain injury during venoarterial-extracorporeal membrane oxygenation That said, central cannulation provides antegrade flow, meaning blood travels the natural direction through the aorta, which can be an advantage in specific situations where differential hypoxia is a concern.
The Left Ventricle Problem
Here is an underappreciated paradox of VA ECMO: while it keeps the body’s organs alive, it can actually make the heart’s job harder. In peripheral VA ECMO, the pump pushes oxygenated blood retrograde up the aorta. This raises the pressure the left ventricle has to push against when it tries to eject blood. If the heart is already too weak to open the aortic valve, blood backs up in the left ventricle, the chamber distends, wall stress climbs, and myocardial oxygen demand rises at exactly the moment the muscle can least afford it.7PubMed Central. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation Left untreated, this distension can flood the lungs with fluid and prevent the heart from recovering at all.
The solution is left ventricular unloading, which means using an additional device or procedure to drain excess volume from the left side of the heart. Options include intra-aortic balloon pumps, microaxial flow pumps like the Impella, percutaneous drainage of the left atrium, or surgical venting through the left ventricle directly. Each approach works differently: some push blood forward through the aortic valve to reduce the volume inside the chamber, while others drain blood from the left atrium and reduce filling pressure upstream.8Acute and Critical Care. Left ventricle unloading during veno-arterial extracorporeal membrane oxygenation: review with updated evidence The goal across all strategies is to reduce the mechanical overload on the heart, giving it a better chance at recovery.9PubMed Central. Unloading the Left Ventricle in Venoarterial ECMO: In Whom, When, and How?
Harlequin Syndrome
One of the more dramatic complications of peripheral VA ECMO goes by several names: Harlequin syndrome, North-South syndrome, or differential hypoxia. It occurs when the heart starts to recover some pumping ability but the lungs remain sick. The recovering heart ejects poorly oxygenated blood forward from the left ventricle, while the ECMO circuit pushes well-oxygenated blood backward from the femoral artery. These two streams collide somewhere in the aorta, and the mixing zone determines which organs get good oxygen and which do not. If the heart’s output is strong enough, the poorly oxygenated blood supplies the brain and the coronary arteries while the well-oxygenated ECMO blood supplies only the lower body. The reported incidence sits around 9%.10PubMed Central. Criticare 2025 Abstracts Supplement ECPR and Harlequin Syndrome
Clinicians monitor for this by placing a pulse oximeter on the right hand, which is supplied by blood coming from the heart, and comparing it to the reading from a lower extremity. A significant gap signals trouble. Management options include improving lung function (clearing mucus plugs, adjusting ventilator settings, draining excess fluid), cranking up the ECMO flow to overwhelm the heart’s output, using beta-blockers to temporarily dampen the heart’s ejection, or relocating the arterial return cannula to the subclavian artery or directly to the aorta so oxygenated blood reaches the upper body first.11PubMed Central. Criticare 2025 Abstracts Supplement ECPR and Harlequin Syndrome
Limb Ischemia
When a large arterial cannula sits inside the femoral artery, it can obstruct blood flow to the leg downstream of the insertion point. The leg goes pale, cold, and can develop irreversible damage if perfusion is not restored. This is one of the most feared vascular complications of peripheral VA ECMO, and it prompted the widespread adoption of distal perfusion catheters: a smaller tube inserted into the artery beyond the cannula site, delivering a portion of the ECMO circuit’s oxygenated blood directly to the leg.
The evidence on how to use these catheters is still evolving. One study found that the key risk factors for limb ischemia were the absence of a distal perfusion catheter at the time of cannulation and the use of a smaller arterial cannula.12PubMed. Arterial protocol including prophylactic distal perfusion catheter decreases limb ischemia complications in patients undergoing extracorporeal membrane oxygenation Another study found no difference in limb complications when preemptive catheters were not placed, though delayed insertion successfully resolved ischemic symptoms when they developed.13PubMed Central. Distal Perfusion Cannulation and Limb Complications in Venoarterial Extracorporeal Membrane Oxygenation Recent work on catheter design has shown that removing the side port connector from a distal perfusion catheter can increase flow by over 200%, which could further reduce ischemia risk.14PubMed Central. Novel Use of a Distal Perfusion Catheter With a Removable Side Port in Patients on VA-ECMO Many centers now place these catheters routinely at the time of cannulation, though the practice is not universal.
Neurological Injury
Brain injury during VA ECMO is common and devastating. A meta-analysis comparing the two ECMO modes found that roughly 17% of VA ECMO patients developed neurological complications, compared with about 10% on VV ECMO. VA ECMO carried significantly higher rates of ischemic stroke, hypoxic-ischemic brain injury, and brain death, though intracranial hemorrhage rates were similar between the two modes.15Neurology. Comparison of Neurologic Complications of Veno-arterial Versus Veno-venous Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis
Data from the Extracorporeal Life Support Organization registry, covering more than 10,000 VA ECMO patients, found ischemic stroke in about 4% and hemorrhagic stroke in about 2%. When stroke occurred, mortality was grim: 76% for ischemic stroke and 86% for hemorrhagic stroke, compared with 56% overall. Modifiable risk factors for ischemic stroke included lower pre-ECMO blood pH, higher oxygen levels on the first day of support, and the need for kidney dialysis. Hemorrhagic stroke was associated with female sex, longer time on ECMO, dialysis, and hemolysis.16PubMed Central. Modifiable Risk factors and mortality from ischemic and hemorrhagic strokes in patients receiving veno-arterial extracorporeal membrane oxygenation The encouraging finding from the same registry was that the rate of reported brain injury dropped from about 10% to 6% over a five-year period, suggesting that growing institutional experience and protocol refinements are making a difference.
Anticoagulation and Bleeding
Blood flowing through plastic tubing and across the ECMO membrane activates clotting pathways, so patients on VA ECMO require continuous anticoagulation. The traditional drug for this is unfractionated heparin, but bivalirudin, a direct thrombin inhibitor, has emerged as an alternative. One study in VA ECMO patients with cardiogenic shock found that bivalirudin was associated with fewer clot-related events per day on the circuit, a longer time before any clot formed, less major bleeding, and lower transfusion requirements compared with heparin.17ASAIO Journal. Bivalirudin Versus Unfractionated Heparin in Patients With Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation However, another study found no significant differences in thrombotic events, bleeding, neurological events, or mortality between the two drugs, concluding that bivalirudin was a viable alternative but not clearly superior.18ASAIO Journal. Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane Oxygenation The bottom line for now is that bivalirudin gives clinicians a second option, particularly useful for patients who develop heparin-induced thrombocytopenia, but neither drug has won a definitive head-to-head trial in this population.
Beyond the choice of anticoagulant, the contact between blood and the non-biological surfaces of the ECMO circuit triggers a broader inflammatory response resembling what happens during cardiopulmonary bypass in open-heart surgery. The immune system recognizes the foreign surface and activates clotting, complement, and white blood cells, potentially leading to organ injury on top of whatever insult brought the patient to ECMO in the first place.19PubMed Central. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology Newer circuit materials aim to reduce this reaction through heparin coatings, nitric-oxide-releasing surfaces, and membranes designed to mimic the lining of natural blood vessels.20PubMed Central. What Are the Best Biocompatible Materials for Extracorporeal Membrane Oxygenation
Extracorporeal CPR
One of the most dramatic uses of VA ECMO is during cardiac arrest itself, known as extracorporeal cardiopulmonary resuscitation or ECPR. When a patient’s heart stops and conventional CPR with defibrillation cannot restore a rhythm, a team cannulates the patient and starts the ECMO circuit while chest compressions are still ongoing. The idea is compelling: mechanical circulatory support should keep the brain and organs alive far longer than manual CPR alone. But translating that logic into proven survival benefit has been harder than expected.
Dedicated single-center programs with specialized teams can get a patient from cardiac arrest to ECMO flow in about 60 minutes, and they report encouraging survival numbers. However, these results have been difficult to reproduce in broader settings.21PubMed Central. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest – current status A randomized trial from Prague compared ECPR with conventional CPR for out-of-hospital cardiac arrest and found no statistically significant difference: about 20% of the ECPR group had a good neurological outcome at 30 days versus 16% in the conventional group.22PubMed. Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest Observational data suggest that younger patients and those with shorter times from collapse to ECMO flow do better, which makes intuitive sense: less time without adequate circulation means less brain and organ damage.23Scientific Reports. Extracorporeal cardiopulmonary resuscitation for patients with refractory out-of-hospital cardiac arrest The field is still working out which patients benefit most and whether ECPR programs can scale beyond high-volume expert centers.
Combining VA ECMO with an Intra-Aortic Balloon Pump
Given the left ventricular overload problem described earlier, clinicians have tried pairing VA ECMO with an intra-aortic balloon pump (IABP), a device that inflates and deflates in sync with the heartbeat to reduce the afterload the heart pushes against and improve coronary blood flow. A large nationwide Japanese study of patients with acute myocardial infarction and cardiogenic shock found that the combination of VA ECMO plus IABP was associated with substantially lower in-hospital, 7-day, and 30-day mortality compared with VA ECMO alone.24PubMed Central. Outcomes of Venoarterial Extracorporeal Membrane Oxygenation Plus Intra-Aortic Balloon Pumping for Treatment of Acute Myocardial Infarction Complicated by Cardiogenic Shock Another study of postcardiotomy shock patients found that the combination achieved a weaning rate above 80% and a one-year survival rate of about 76%, both significantly better than either device used alone.25PubMed Central. Comparison of ECMO, IABP and ECMO + IABP in the Postoperative Period in Patients with Postcardiotomy Shock These are observational data and therefore subject to selection bias, but the consistency of the signal across multiple studies has led many centers to adopt the combination as a default strategy.
Weaning Off VA ECMO
VA ECMO is not a destination. It is a bridge, and the critical clinical question is when and whether the patient can come off it. Weaning involves gradually reducing the ECMO flow rate while monitoring whether the heart can handle the load on its own. Clinicians use echocardiography during this process, watching for signs of left and right ventricular recovery.
A systematic review found that the most widely used predictor of successful weaning was the velocity-time integral measured at the left ventricular outflow tract, which is essentially an ultrasound-based estimate of how much blood the heart pushes out with each beat.26PubMed Central. Parameters associated with successful weaning of veno-arterial extracorporeal membrane oxygenation: a systematic review A more recent study added a surprising finding: the traditional measure of heart function, ejection fraction, did not actually predict weaning success. Instead, measurements of longitudinal heart muscle motion and indicators of how efficiently the heart was filling and ejecting were far more reliable.27PubMed. Echocardiographic parameters for weaning from extracorporeal membrane oxygenation-the role of longitudinal function and cardiac time intervals This matters because ejection fraction is the number most clinicians and patients are familiar with, and it turns out to be misleading in this context.
Bridge to Transplant or Ventricular Assist Device
When the heart does not recover enough to come off VA ECMO, the next step is often transition to a more durable form of support. Registry data show that the use of VA ECMO as a bridge to either a left ventricular assist device (LVAD) or heart transplant has grown over time, with more patients now going to LVADs than directly to transplant.28PubMed Central. Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock Among patients bridged from ECMO, mortality appears similar whether the destination is an LVAD or a transplanted heart.29PubMed. ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation That said, patients bridged with VA ECMO to transplant tend to have lower survival than patients who go to transplant without needing ECMO beforehand, reflecting the severity of illness and accumulated organ damage during the ECMO run.30PubMed Central. Veno-arterial Extracorporeal Membrane Oxygenation as Bridge to Heart Transplantation: The Way Forward
Pediatric VA ECMO
Children and neonates represent a significant proportion of VA ECMO use, particularly for congenital heart disease and cardiomyopathy. A meta-analysis of pediatric heart disease patients found a pooled short-term mortality of about 46%, with outcomes varying sharply by diagnosis. Children with acute fulminant myocarditis fared considerably better than those with congenital heart disease. Older and heavier children also did better, while male sex, bleeding complications, kidney injury, and central cannulation were all associated with higher mortality.31PubMed Central. Short-Term Mortality Among Pediatric Patients With Heart Diseases Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis A single-center study of pediatric VA ECMO patients with mixed indications reported survival to discharge of about 55% and one-year survival of about 48%.32PubMed. Predictors of Poor Outcomes in Pediatric Venoarterial Extracorporeal Membrane Oxygenation
Long-Term Outcomes and Quality of Life
Surviving VA ECMO and leaving the hospital is only the beginning. A systematic review and meta-analysis of long-term outcomes found that roughly 41% of ECMO survivors had neuropsychiatric symptoms, including pain and discomfort in over half, anxiety in about a third, depression in about a third, and post-traumatic stress disorder in close to one in five.33PubMed Central. Long-Term Neuropsychiatric, Neurocognitive, and Functional Outcomes of Patients Receiving ECMO: A Systematic Review and Meta-Analysis Functional impairment affected about half of survivors, with limitations in daily activities and mobility being the most common. Interestingly, neuropsychiatric symptoms were more prevalent among VV ECMO survivors than VA ECMO survivors in this analysis, possibly because VV ECMO patients start with severe respiratory illness that carries its own psychological burden. But VA ECMO survivors specifically faced worse physical function overall, and complications like neurological injury and limb ischemia were major contributors to long-term disability.34JHLT Open. Long-term quality of life and functional outcomes in extracorporeal membrane oxygenation survivors
A review focused specifically on VA ECMO survivors found that physical, emotional, and cognitive recovery was worse than what would be expected in the general population and approached the level of impairment seen in people living with chronic disease. High rates of depression, anxiety, and PTSD persisted for years. Half or fewer survivors returned to work.35PubMed Central. Sounding the Alarm: What Clinicians Need to Know about Physical, Emotional, and Cognitive Recovery After Venoarterial Extracorporeal Membrane Oxygenation Almost no studies had examined cognitive function in the first year after discharge, a gap that makes it hard to plan early rehabilitation. The message is clear: survival alone is not enough, and the field needs to invest in structured follow-up and recovery programs.
What VA ECMO Costs
VA ECMO is extraordinarily expensive. An analysis of U.S. hospital data found that the mean cost for a continuous VA ECMO hospitalization was about $245,000, with a median around $191,000.36PubMed Central. Extracorporeal Membrane Oxygenation (ECMO) and hospital economics When a left ventricular unloading device like the Impella was added to VA ECMO for cardiogenic shock, median total inpatient costs climbed from about $320,000 to roughly $390,000, and daily costs were over four times higher than for patients receiving neither device.37PubMed Central. Hospital costs associated with mechanical left ventricular mechanical unloading devices during VA ECMO for adult cardiogenic shock Length of stay is the dominant driver: hospitalizations with shorter stays were the ones where payments actually covered costs, while longer stays produced large financial deficits for hospitals. These economics shape which institutions offer VA ECMO, how aggressively they deploy it, and how conversations about goals of care unfold when recovery stalls.
Ethics of Withdrawal
VA ECMO raises uniquely difficult ethical questions. Unlike a ventilator, which assists breathing but does not replace the heartbeat, VA ECMO can be the sole reason a patient’s blood continues to circulate. Withdrawing it in a patient whose heart has not recovered is, in a very direct sense, allowing them to die. This creates psychological weight for families and clinicians alike. Ethicists and clinical guidelines emphasize that withholding and withdrawing a treatment are morally equivalent: a patient should not be denied a potentially beneficial trial of ECMO simply because people fear that stopping it later would be too difficult. The value of a time-limited trial, where ECMO is started with a clear reassessment point, is that it allows prognosis to be clarified while keeping the patient alive.38PubMed Central. Decisions to Withdraw Extracorporeal Membrane Oxygenation Support: Patient Characteristics and Ethical Considerations In practice, these conversations happen under extreme time pressure, often with families who had no warning their loved one would need mechanical circulatory support. Early palliative care involvement and transparent communication about what VA ECMO can and cannot achieve remain areas where many programs are still building their frameworks.